title: Speed bumps on the road to a chemotherapy-free world for lymphoma patients.
abstract: With the increasing number of targeted agents for the treatment of patients with lymphoid malignancies comes the promise of safe and effective chemotherapy-free treatment strategies. A number of single agents, such as ibrutinib and idelalisib, have demonstrated impressive efficacy with a favorable toxicity profile. The observations that most responses are, however, partial and treatment duration is indefinite have stimulated interest in combinations of these agents with chemotherapy as well as with each other. Despite the promise of this approach, several recent trials of combinations of agents have been terminated as the result of life-threatening and fatal complications. Such outcomes have generated a cautionary note of the potential for unforeseen adverse effects that challenge drug development and mitigate against the empiric combination of such drugs outside of a clinical trial setting.
authors.affiliation: Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC.
authors.forename: Bruce D
authors.initials: BD
authors.lastname: Cheson
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D002986:Clinical Trials as Topic; D015195:Drug Design; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy* / Q000401:mortality; D010880:Piperidines; D011687:Purines / Q000627:therapeutic use*; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D052999:Quinazolinones / Q000627:therapeutic use*
chemical_list: D010880:Piperidines; D011687:Purines; D011720:Pyrazoles; D011743:Pyrimidines; D052999:Quinazolinones; C551803:ibrutinib; D000225:Adenine; C552946:idelalisib